Clinical Trials Logo

Clinical Trial Summary

This is a research study of an investigational drug called ambrisentan (Letairis) in the treatment and prevention of digital ulcers in patients with systemic sclerosis.


Clinical Trial Description

Ambrisentan is an endothelin blocker approved for the treatment of pulmonary arterial hypertension. Patients with systemic sclerosis can have damage to their blood vessels, resulting in increased levels of endothelin in their bloodstream that then causes decreased blood flow to the digits. This can result in very painful digital ulcers. We hope to learn whether blocking the action of endothelin with ambrisentan will be helpful in the treatment and prevention of digital ulcers in patients with systemic sclerosis. This therapy is not approved for the treatment of systemic sclerosis, but this study will help us learn whether ambrisentan is safe and effective in the treatment and prevention of digital ulcers in patients with systemic sclerosis. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00725361
Study type Interventional
Source Stanford University
Contact
Status Completed
Phase N/A
Start date June 2008
Completion date December 2010

See also
  Status Clinical Trial Phase
Completed NCT03965780 - The SPIN - Scleroderma Support Group Leader EDucation Program Trial (SPIN-SSLED) N/A
Terminated NCT02558543 - Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis Phase 2
Withdrawn NCT01202045 - Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients N/A
Terminated NCT01445821 - Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial Phase 3
Recruiting NCT05878717 - A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease Phase 3
Recruiting NCT03559465 - Profibrosing Role of B Lymphocytes in Patients With Systemic Sclerosis. N/A
Not yet recruiting NCT03610217 - Pragmatic Clinical Trials in Scleroderma N/A
Completed NCT02655640 - The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis N/A
Completed NCT05622578 - Phenotyping of Chronic Pain in Diffused Systemic Scleroderma N/A
Recruiting NCT04804930 - Trichoscopy and Systemic Scleroderma
Completed NCT03675581 - A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) Phase 1
Completed NCT03221257 - Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate Phase 2
Recruiting NCT05559580 - A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms Phase 2
Completed NCT00442611 - A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma) Phase 1/Phase 2
Completed NCT00001330 - Study of Silicone-Associated Connective Tissue Diseases N/A
Completed NCT02597933 - A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis Phase 3
Not yet recruiting NCT05821335 - Leap Motion Based Gamefication Exercises in the Individuals With Systemic Sclerosis N/A
Completed NCT00333437 - Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement N/A
Completed NCT00025818 - Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Phase 3
Not yet recruiting NCT05351060 - Novel Splinting Technique Using 3D Models N/A